**GlaxoSmithKline Expands Cambridge Footprint with Full Building Takeover**
British pharmaceutical giant GlaxoSmithKline (GSK) is significantly expanding its presence in Cambridge, Massachusetts. The company will occupy the entire 222,000-square-foot building at 200 CambridgePark Drive, a six-story property owned by King Street Properties. The site is set to accommodate approximately 400 employees.
According to the Boston Business Journal, this expansion follows GSK’s recent decision to relocate its vaccine research and development (R&D), as well as its infectious disease teams, from Maryland to Cambridge.
Chris Austin, Senior Vice President of Research Technologies at GSK, shared with the publication that staffing the new facility will involve a mix of transferring employees from Maryland and hiring locally in Massachusetts. He emphasized that GSK originally expanded into the Boston area nearly a decade ago to leverage the region’s unparalleled talent base.
“Cambridge and Boston in general, in my view, is still untouchable there, and it’s one of the reasons why we located here and will continue to expand here,” Austin said.
GSK currently operates two other facilities in Cambridge, although it is not yet clear what the company’s plans are for those locations following the expansion.
